In the US, anti–vascular endothelial growth factor (VEGF) medications are typically distributed to hospitals and clinics by wholesalers. Transport and storage conditions are regulated by the US Food and Drug Administration. However, in countries such as France, patients typically purchase their own anti-VEGF agents at the pharmacy and bring them to their ophthalmologists for administration, thus introducing the possibility of suboptimal storage conditions.
Leave a Reply